Compare Stocks: ALEC, RGNX, KRYS, IMVT, and OCGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.08 +3.0%	$2.08	$1.09 ▼ $3.40	$232.25M	0.62	6.62 million shs	3.10 million shs
IMVT Immunovant	$30.47 +0.7%	$38.41	$16.59 ▼ $45.42	$6.29B	0.84	1.61 million shs	1.49 million shs
KRYS Krystal Biotech	$331.61 +1.3%	$340.04	$179.19 ▼ $382.54	$9.82B	0.5	306,995 shs	196,948 shs
OCGN Ocugen	$0.96 -2.2%	$1.20	$0.90 ▼ $2.73	$324.02M	2.27	7.31 million shs	13.29 million shs
RGNX REGENXBIO	$8.07 -0.2%	$9.06	$5.45 ▼ $16.19	$532.72M	1.13	1.53 million shs	859,079 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	+14.92%	-2.80%	+29.19%	-32.47%
IMVT Immunovant	0.00%	-9.37%	-20.03%	-23.27%	+89.49%
KRYS Krystal Biotech	0.00%	+2.89%	-4.03%	-9.35%	+77.16%
OCGN Ocugen	0.00%	-6.32%	-6.78%	-35.00%	-46.62%
RGNX REGENXBIO	0.00%	+8.61%	-5.72%	-42.15%	-33.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.08 +3.0%	$2.08	$1.09 ▼ $3.40	$232.25M	0.62	6.62 million shs	3.10 million shs
IMVT Immunovant	$30.47 +0.7%	$38.41	$16.59 ▼ $45.42	$6.29B	0.84	1.61 million shs	1.49 million shs
KRYS Krystal Biotech	$331.61 +1.3%	$340.04	$179.19 ▼ $382.54	$9.82B	0.5	306,995 shs	196,948 shs
OCGN Ocugen	$0.96 -2.2%	$1.20	$0.90 ▼ $2.73	$324.02M	2.27	7.31 million shs	13.29 million shs
RGNX REGENXBIO	$8.07 -0.2%	$9.06	$5.45 ▼ $16.19	$532.72M	1.13	1.53 million shs	859,079 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	+14.92%	-2.80%	+29.19%	-32.47%
IMVT Immunovant	0.00%	-9.37%	-20.03%	-23.27%	+89.49%
KRYS Krystal Biotech	0.00%	+2.89%	-4.03%	-9.35%	+77.16%
OCGN Ocugen	0.00%	-6.32%	-6.78%	-35.00%	-46.62%
RGNX REGENXBIO	0.00%	+8.61%	-5.72%	-42.15%	-33.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.11	Hold	$3.40	63.46% Upside
IMVT Immunovant	2.58	Moderate Buy	$44.00	44.40% Upside
KRYS Krystal Biotech	3.00	Buy	$377.20	13.75% Upside
OCGN Ocugen	2.60	Moderate Buy	$9.50	894.24% Upside
RGNX REGENXBIO	2.71	Moderate Buy	$23.17	187.07% Upside

Current Analyst Ratings Breakdown

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
10/6/2026	ALEC Alector	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$2.00 ➝ $3.00
10/6/2026	ALEC Alector	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$1.50
10/5/2026	RGNX REGENXBIO	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
10/5/2026	RGNX REGENXBIO	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
10/2/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/28/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/24/2026	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive
9/24/2026	KRYS Krystal Biotech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$441.00

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$21.05M	11.03	N/A	N/A	$0.28 per share	7.43
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
KRYS Krystal Biotech	$389.13M	25.22	$7.29 per share	45.49	$42.06 per share	7.88
OCGN Ocugen	$4.41M	73.47	N/A	N/A	($0.04) per share	-23.89
RGNX REGENXBIO	$170.44M	3.13	N/A	N/A	$2.03 per share	3.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$142.93M	-$1.10	N/A	N/A	N/A	-850.13%	-531.03%	-44.00%	11/5/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	41.56	36.20	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
OCGN Ocugen	-$67.85M	-$0.26	N/A	N/A	N/A	N/A	-127,987.80%	-115.95%	11/4/2026 (Estimated)
RGNX REGENXBIO	-$193.88M	-$3.79	N/A	N/A	N/A	-112.58%	-220.07%	-46.04%	11/5/2026 (Estimated)

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ALEC Alector	-$0.23	N/A	N/A	N/A	$2.38 million	N/A
11/5/2026	Q3 2026	RGNX REGENXBIO	-$1.2992	N/A	N/A	N/A	$14.87 million	N/A
11/4/2026	Q3 2026	OCGN Ocugen	-$0.06	N/A	N/A	N/A	$1.32 million	N/A
11/2/2026	Q3 2026	KRYS Krystal Biotech	$1.86	N/A	N/A	N/A	$128.49 million	N/A
8/6/2026	Q2 2026	ALEC Alector	-$0.2286	-$0.21	+$0.0186	-$0.21	$1.71 million	$3.32 million
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/6/2026	Q2 2026	OCGN Ocugen	-$0.0533	-$0.07	-$0.0167	-$0.07	$0.89 million	$1.49 million
8/6/2026	Q2 2026	RGNX REGENXBIO	$0.0787	$0.43	+$0.3513	$0.43	$97.63 million	$108.02 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.80	5.26	5.26
IMVT Immunovant	N/A	7.27	7.27
KRYS Krystal Biotech	N/A	8.32	7.96
OCGN Ocugen	4.17	0.80	0.80
RGNX REGENXBIO	N/A	2.86	2.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
IMVT Immunovant	47.08%
KRYS Krystal Biotech	86.29%
OCGN Ocugen	10.27%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
ALEC Alector	8.30%
IMVT Immunovant	1.90%
KRYS Krystal Biotech	13.10%
OCGN Ocugen	3.95%
RGNX REGENXBIO	14.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	103	111.66 million	102.39 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable
OCGN Ocugen	116	339.11 million	325.72 million	Optionable
RGNX REGENXBIO	371	66.01 million	56.63 million	Optionable

ALEC, RGNX, KRYS, IMVT, and OCGN Headlines

Recent News About These Companies

REGENXBIO (NASDAQ:RGNX) Stock Rating Raised to Strong-Buy at Mizuho

October 6, 2026 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Raised to "Strong-Buy" at Mizuho

October 6, 2026 | marketbeat.com

Mizuho initiates coverage of REGENXBIO at outperform

October 6, 2026 | msn.com

REGENXBIO (NASDAQ:RGNX) Stock Jumps 8.1% - What's Next?

October 5, 2026 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Shares Climb 8.1% - What's Next?

October 5, 2026 | marketbeat.com

Mizuho Initiates REGENXBIO at Outperform With $22 Price Target

October 5, 2026 | finance.yahoo.com

Regenxbio’s two lead gene therapies back Mizuho’s nearly 200% upside call

October 5, 2026 | msn.com

REGENXBIO Inc. $RGNX Shares Newly Purchased by Bank of America Corp DE

September 28, 2026 | marketbeat.com

REGENXBIO reports three-year ALTITUDE results for sura-vec diabetic retinopathy program

September 25, 2026 | grafa.comG

REGENXBIO stock reports 60 percent three-year eye study response

September 25, 2026 | ad-hoc-news.deA

Regenxbio基因療法試驗數據積極，股價盤前上漲4.8%

September 25, 2026 | hk.finance.yahoo.com

Regenxbio stock gains on positive gene therapy trial data

September 25, 2026 | finance.yahoo.com

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

September 24, 2026 | prnewswire.com

Regenxbio settles patent dispute with Sarepta for $39M

September 24, 2026 | streetinsider.com

REGENXBIO (NASDAQ:RGNX) Stock Price Passes Below 50-Day Moving Average - Time to Sell?

September 23, 2026 | marketbeat.com

Corient Private Wealth LP Makes New $2.61 Million Investment in REGENXBIO Inc. $RGNX

September 23, 2026 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages

September 23, 2026 | marketbeat.com

REGENXBIO stock edges lower as short interest stays elevated

September 20, 2026 | ad-hoc-news.deA

REGENXBIO Inc. (RGNX) Stock Price, News, Quote & History - Yahoo Finance

September 16, 2026 | finance.yahoo.com

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

REGENXBIO Inc. (RGNX) Presents at 2026 Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, RGNX, KRYS, IMVT, and OCGN Company Descriptions

Alector NASDAQ:ALEC

$2.08 +0.06 (+2.97%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.07 -0.01 (-0.48%)

As of 10/9/2026 07:52 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Immunovant NASDAQ:IMVT

$30.47 +0.21 (+0.69%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$30.48 +0.01 (+0.02%)

As of 10/9/2026 07:30 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Krystal Biotech NASDAQ:KRYS

$331.61 +4.31 (+1.32%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$327.07 -4.54 (-1.37%)

As of 10/9/2026 07:30 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Ocugen NASDAQ:OCGN

$0.96 -0.02 (-2.24%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.96 +0.00 (+0.37%)

As of 10/9/2026 07:57 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

REGENXBIO NASDAQ:RGNX

$8.07 -0.02 (-0.25%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$8.14 +0.07 (+0.92%)

As of 10/9/2026 07:59 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, RGNX, KRYS, IMVT, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, RGNX, KRYS, IMVT, and OCGN Company Descriptions

Alector NASDAQ:ALEC

Immunovant NASDAQ:IMVT

Krystal Biotech NASDAQ:KRYS

Ocugen NASDAQ:OCGN

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, RGNX, KRYS, IMVT, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, RGNX, KRYS, IMVT, and OCGN Company Descriptions

Alector NASDAQ:ALEC

Immunovant NASDAQ:IMVT

Krystal Biotech NASDAQ:KRYS

Ocugen NASDAQ:OCGN

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools